Health-related quality of life with belzutifan versus everolimus for advanced kidney cancer
People with kidney cancer have been shown to have changes (mutations) in [...]
Belzutifan compared to everolimus for advanced kidney cancer
People with kidney cancer have been shown to have changes (mutations) in [...]
Lenvatinib plus everolimus for patients with metastatic kidney cancer
The treatment of heavily pretreated patients with metastatic kidney cancer [...]
METEOR study: Cabozantinib compared to everolimus in advanced kidney cancer
Cabozantinib is a tyrosine kinase inhibitor that is used [...]
Belzutifan significantly delays progression of advanced kidney cancer after other treatments have failed
Kidney cancers often have mutations in a gene called the von Hippel-Lindau [...]
Health-related quality of life with lenvatinib in combination with everolimus
Maintaining good health-related quality of life is important for all [...]
Can adjuvant everolimus prevent recurrence following surgery?
At the American Society of Clinical Oncology (ASCO) Annual Meeting [...]
Telaglenastat plus everolimus in advanced kidney cancer
This phase 2 clinical trial (ENTRATA) looked at how safe [...]
Telaglenastat plus cabozantinib or everolimus for advanced/metastatic kidney cancer
This phase 1 clinical trial looked at the safety, tolerability, [...]
ASCO GU 2021: Combinations of lenvatinib plus pembrolizumab or everolimus improved survival in untreated patients with advanced kidney cancer
Results from the phase 3 CLEAR study, presented at the [...]
